Ainos advances Veldona oral interferon drug platform

Ainos (AIMD) announced progress in advancing its oral interferon drug platform, Veldona in the rare disease space. The Taiwan FDA has approved the company’s clinical trial for human immunodeficiency virus-related oral warts, while Institutional Review Board clearance has been granted for its upcoming Sjogren’s Syndrome study. The upcoming Taiwan trials will be conducted using the company’s next-generation Veldona formulation.